REGULATORY

• MHLW Taking Applications for Subsidies to Support Generic Consolidation, Biosimilars
  March 6, 2025

• Japan’s FY2025 Draft Budget Clears Lower House
  March 5, 2025

• Three-Party Talks to Be Held on Health Coverage of OTC-Like Drugs: Minister
  March 4, 2025

• No Prior Talks with US Drug Makers for Deferred PMP Price Cuts: Health Minister
  March 3, 2025

• Japan Grants Orphan Tags to Atrasentan, Efzimfotase, and Lots More
  March 3, 2025

• Japan to Revisit Copay Cap Hike Plan for 2026 and Beyond: Ishiba
  March 3, 2025

• Japan Extends Re-Examination Period for Zeposia, Lupkynis
  March 3, 2025

• Japan to Launch Pilot Project for Adopting Fair Market Value in Clinical Trial Costs
  February 28, 2025

• LDP Lawmakers Urge Generic Industry to Ramp Up Production
  February 28, 2025

• J&J’s Lazcluze, Genmab’s Tivdak and More Drugs in Line for Japan Approval
  February 28, 2025

• LDP, Komeito, Ishin Agree to Set Up Consultive Body for Social Security Reform
  February 26, 2025

• Coordinate Patent Issues with Originators before Listing: MHLW to Generic Firms
  February 26, 2025

• Care Avoidance from Copay Cap Hike Likely to Result in 195 Billion Yen Cost Reduction
  February 25, 2025

• PMDA Lists Info Needed for Pediatric Development Plan Confirmation
  February 25, 2025

• MHLW to Shorten Procedure for Generic Product Integration to 1.5 Months
  February 21, 2025

• Takeda’s Livmarli, BMS’s Camzyos and More Up for MHLW Panel Review on March 6
  February 21, 2025

• Japan to Pen Fact Sheet for Sanofi’s High-Dose Flu Jab
  February 21, 2025

• Japan Approves CSL’s HAE Med Andembry, Tecentriq Sarcoma Use, and More
  February 21, 2025

• Ex-Lawmakers Launch Council for Revamping Japan’s Drug Innovation
  February 20, 2025

• Chuikyo OKs Pricing Rules for FY2025 Drug Price Revision
  February 20, 2025

ページ

• « 先頭
• ‹ Prev
• …
• 27
• 28
• 29
• 30
• 31
• 32
• 33
• 34
• 35
• …
• Next ›
• 最終 »